Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture.

Lanske B, Chandler H, Pierce A, Brown J, Ominsky M, Kostenuik P, Hattersley G

Journal of orthopaedic research : official publication of the Orthopaedic Research Society21 Mar 2019Cited by 21 (Europe PMC)

PMID30790359DOI10.1002/jor.24254PepBankPUB-30790359

Source link PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, abaloparatide groups had greater total callus area than vehicle controls.
In plain wordsIn rats with femoral fractures, abaloparatide increased total callus area compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal callus area
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
Histomorphometry and histology analyses indicated that fracture calluses from the abaloparatide groups exhibited significantly greater total area, higher fluorescence scores indicating more newly-formed bone, and higher fracture bridging scores versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035901
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, abaloparatide groups had higher callus fluorescence scores than vehicle controls.
In plain wordsIn rats with femoral fractures, abaloparatide increased scores for newly formed bone compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus fluorescence score
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
Histomorphometry and histology analyses indicated that fracture calluses from the abaloparatide groups exhibited significantly greater total area, higher fluorescence scores indicating more newly-formed bone, and higher fracture bridging scores versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035902
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, abaloparatide groups had higher fracture bridging scores than vehicle controls.
In plain wordsIn rats with femoral fractures, abaloparatide increased fracture bridging scores compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFracture bridging score
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
Histomorphometry and histology analyses indicated that fracture calluses from the abaloparatide groups exhibited significantly greater total area, higher fluorescence scores indicating more newly-formed bone, and higher fracture bridging scores versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035903
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, one or both abaloparatide groups had greater callus bone volume than vehicle at both time points.
In plain wordsIn rats with femoral fractures, one or both abaloparatide groups had more callus bone volume than vehicle at both time points.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus bone volume
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
By micro-CT, calluses from one or both abaloparatide groups had greater bone volume, bone volume fraction, bone mineral content, bone mineral density, and cross-sectional area at both time points versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035904
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, one or both abaloparatide groups had greater callus bone volume fraction than vehicle at both time points.
In plain wordsIn rats with femoral fractures, one or both abaloparatide groups had higher callus bone volume fraction than vehicle at both time points.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus bone volume fraction
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
By micro-CT, calluses from one or both abaloparatide groups had greater bone volume, bone volume fraction, bone mineral content, bone mineral density, and cross-sectional area at both time points versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035905
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, one or both abaloparatide groups had greater callus bone mineral content than vehicle at both time points.
In plain wordsIn rats with femoral fractures, one or both abaloparatide groups had higher callus bone mineral content than vehicle at both time points.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus bone mineral content
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
By micro-CT, calluses from one or both abaloparatide groups had greater bone volume, bone volume fraction, bone mineral content, bone mineral density, and cross-sectional area at both time points versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035906
07AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, one or both abaloparatide groups had greater callus bone mineral density than vehicle at both time points.
In plain wordsIn rats with femoral fractures, one or both abaloparatide groups had higher callus bone density than vehicle at both time points.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus bone mineral density
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
By micro-CT, calluses from one or both abaloparatide groups had greater bone volume, bone volume fraction, bone mineral content, bone mineral density, and cross-sectional area at both time points versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035907
08AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, one or both abaloparatide groups had greater callus cross-sectional area than vehicle at both time points.
In plain wordsIn rats with femoral fractures, one or both abaloparatide groups had larger callus cross-sections than vehicle at both time points.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus cross-sectional area
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
By micro-CT, calluses from one or both abaloparatide groups had greater bone volume, bone volume fraction, bone mineral content, bone mineral density, and cross-sectional area at both time points versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035908
09AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, one or both abaloparatide groups had greater callus maximum load than vehicle at both time points.
In plain wordsIn rats with femoral fractures, one or both abaloparatide groups tolerated greater callus loads than vehicle at both time points.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus maximum load
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
Destructive bending tests indicated greater callus maximum load and stiffness in one or both abaloparatide groups at both time points versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035909
10AnimalAnimal study (in vivo)Efficacy outcome
In rats with femoral fractures, one or both abaloparatide groups had greater callus stiffness than vehicle at both time points.
In plain wordsIn rats with femoral fractures, one or both abaloparatide groups had stiffer calluses than vehicle at both time points.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCallus stiffness
Study
ratn: not reported in source
Internally stabilized femoral fracture
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/d · subcutaneous · 4 or 6 weeksAs given in this study (rat).
Source sentences
Summary
Destructive bending tests indicated greater callus maximum load and stiffness in one or both abaloparatide groups at both time points versus Vehicle controls.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, ninety-six 12-week-old male rats underwent unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks (16 rats/group/time point).
Report a problemFND-3079035910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04249232

Abaloparatide and Pelvic Fracture Healing

Hospital for Special Surgery, New Yorkn = 4817 Sept 2020 to 25 Apr 2024

Fracture of Pelvis (Disorder)

Trial page ClinicalTrials.govUpdated 14 Jun 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.